The objective of this study was to assess the response of anxiety and depression symptoms to methylphenidate (MPH) treatment in patients with Asperger syndrome (AS) combined with attention deficit/hyperactivity disorder (ADHD). A group of 12 patients with AS/ADHD, aged 8-18 years, received 12 weeks of MPH treatment. The severities of ADHD, anxiety, and depression symptoms were assessed by means of the ADHD Rating Scale (ADHD-RS), Screen for Child Anxiety Related Emotional Disorders, and the Children's Depression Inventory. The severity of ADHD and depression symptoms was reduced significantly (P<0.0003 and P=0.046, respectively). No improvement in total anxiety symptoms was found, but a significant reduction was obtained in the school-related subscale of the Screen for Child Anxiety Related Emotional Disorders (P=0.0054). A positive correlation was found between the reductions in ADHD-RS and Children's Depression Inventory scores (r=0.59, P=0.039). MPH treatment may be safe, tolerable, and effective in alleviating depression and school-related anxiety symptoms in patients with AS and ADHD.

中文翻译：

---

哌醋甲酯对阿斯伯格综合症和并发注意缺陷多动障碍患者的焦虑和抑郁症状的影响。

这项研究的目的是评估焦虑和抑郁症状对阿斯伯格综合征（AS）合并注意力缺陷/多动障碍（ADHD）患者的哌醋甲酯（MPH）治疗的反应。一组12例8-18岁的AS / ADHD患者接受了12周的MPH治疗。通过注意力缺陷多动症评分量表（ADHD-RS），筛查儿童焦虑相关情绪障碍和儿童抑郁量表来评估注意力缺陷多动症的严重程度，焦虑和抑郁症状。ADHD的严重程度和抑郁症状显着降低（分别为P <0.0003和P = 0.046）。未发现总焦虑症状得到改善，但与儿童焦虑相关的情绪障碍筛查的学校相关子量表却得到了显着降低（P = 0.0054）。在ADHD-RS的减少与儿童抑郁量表得分之间发现正相关（r = 0.59，P = 0.039）。MPH治疗对于缓解AS和ADHD患者的抑郁和学校相关的焦虑症状可能是安全，可耐受和有效的。